

AGIMEXPHARM PHARMACEUTICAL
JOINT STOCK COMPANYTHE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

No.: 37/CBTT-AGP

An Giang, August 7, 2025

PERIODIC DISCLOSURE OF FINANCIAL STATEMENTS

To: Hanoi Stock Exchange

Pursuant to Clause 3, Article 14 of Circular No. 96/2020/TT-BTC dated November 16, 2020, issued by the Ministry of Finance guiding information disclosure on the securities market, Agimexpharm Pharmaceutical Joint Stock Company hereby discloses its interim financial statements for the first 6 months of the fiscal year ending 31 December 2025 to Hanoi Stock Exchange as follows:

1. Organization Name: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

- Securities symbol: AGP
- Address: 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province
- Contact phone: 02963.856964
- Website: <http://agimexpharm.com>

2. Disclosure information content:

- Interim financial statements for the first 6 months of the fiscal year ending 31 December 2025:

☒ Separate Financial Statements (The listed organization has no subsidiaries, and the superior accounting unit has no affiliated units);

☐ Consolidated Financial Statement (The listed organization has subsidiaries);

☐ Combined Financial Statement (The listed organization has affiliated units with separate accounting systems).

- Cases requiring explanation:

+ The auditor provided an opinion that is not full acceptance of the Financial Statements (for the 2024 audited financial statements):

☐ Yes

☒ No

Explanation document if applicable:

☐ Yes

☐ No

+ Profit after tax in the reporting period shows a deviation of 5% or more before and after the audit, or shifts from loss to profit or vice versa (for the 2024 audited financial statements):

☐ Yes

☒ No

Explanation document if applicable:

☐ Yes

☐ No

+ Profit after tax in the income statement of the reporting period changes by 10% or more compared to the same period of the previous year:

☐ Yes

☒ No

Explanation document if applicable:

☐ Yes

☐ No

+ Profit after tax in the reporting period shifts from profit to loss compared to the same period of the previous year or vice versa:

☐ Yes

☒ No

Explanation document if applicable:

☐ Yes

☐ No

This information has been disclosed on the company's website on August 7, 2025 at the link:
<https://agimexpharm.com/shareholder/?lang=en>

Attachments:

- Interim financial statements for the first 6 months of 2025.

Organization Representative
Authorized person for information disclosure



Le Minh Ngoc

INTERIM FINANCIAL STATEMENTS

**FOR THE FIRST 6 MONTHS
OF THE FISCAL YEAR ENDING 31 DECEMBER 2025**

**AGIMEXPARM
PHARMACEUTICAL JOINT
STOCK COMPANY**

CONTENTS

	Page
1. Contents	1
2. Statement of the Board of Management	2 - 4
3. Report on the Review of Interim Financial Information	5
4. Interim Balance Sheet as of 30 June 2025	6 - 9
5. Interim Income Statement for the first 6 months of the fiscal year ending 31 December 2025	10
6. Interim Cash Flow Statement for the first 6 months of the fiscal year ending 31 December 2025	11 - 12
7. Notes to the Interim Financial Statements for the first 6 months of the fiscal year ending 31 December 2025	13 - 39
8. Appendices	40 - 42

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

STATEMENT OF THE BOARD OF MANAGEMENT

The Board of Management of Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") presents this statement together with the Interim Financial Statements for the first 6 months of the fiscal year ending 31 December 2025.

Business highlights

The Company is a joint stock company, which has been operating in accordance with the Business Registration Certificate No. 1600699279, registered for the first time on 03 June 2004 and amended for the 20th time on 01 August 2025, granted by An Giang Province Department of Finance.

Head office

- Address : No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam
- Tel. : (0296) 385 6961- 385 6964
- Fax : (0296) 385 7301

Affiliates:

Affiliate	Address
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 49-51-53, Street No. 3A, An Lac Ward, Ho Chi Minh City
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 42 Nguyen Sinh Sac Street, Hoa Khanh Ward, Da Nang City
Branch of Agimexpharm Pharmaceutical Joint Stock Company - Agimexpharm Pharmaceutical Manufacturing Factory	No. 66 Vu Trong Phung Street, Thanh An Cluster, My Thoi Ward, An Giang Province
Branch of Agimexpharm Pharmaceutical Joint Stock Company – Binh Hoa Factory	Lot C4, Binh Hoa Industrial Park, Binh Hoa Commune, An Giang Province
Agimexpharm Pharmaceutical Joint Stock Company – Central Highlands Branch	No. 184/84 Giai Phong, Buon Ma Thuot Ward, Dak Lak Province
Branch of Agimexpharm Pharmaceutical Joint Stock Company	No. 46, Lane 105, Lang Ha Street, Dong Da Ward, Hanoi City

Principal business activities of the Company are to manufacture medicines, pharmaceutical chemicals and pharmaceutical materials; trade optical, medical, dental and hospital equipment; trade medicines, pharmaceutical products; trade nutritious food; produce and trade cosmetics; trade materials and ancillary materials, pharmaceutical chemicals for pharmaceutical production; trade vaccines and medical biological products; manufacture bottled water (the Company must comply with the Law on food safety and hygiene during operation course); manufacture dietary supplements; manufacture, trade and process essential oil from herbs; manufacture and trade food, nutritious food and dietary supplements.

Board of Management, Supervisory Board and Board of Directors

The Board of Management, the Supervisory Board and the Board of Directors of the Company during the period and as of the date of this statement include:

The Board of Management

Full name	Position	Appointing/re-appointing date
Ms. Pham Thi Bich Thuy	Chairwoman	Re-appointed on 08 April 2023
Mr. Nguyen Van Kha	Vice Chairman	Re-appointed on 08 April 2023
Ms. Tran Thi Dao	Member	Re-appointed on 08 April 2023
Mr. Nguyen Quoc Dinh	Member	Re-appointed on 08 April 2023
Mr. Pham Uyen Nguyen	Member	Re-appointed on 08 April 2023
Mr. Huynh Hoang Ha	Member	Appointed on 08 April 2023

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
STATEMENT OF THE BOARD OF MANAGEMENT (cont.)

The Supervisory Board

Full name	Position	Appointing/re-appointing date
Ms. Tran Thi Thanh Hang	Head of the Board	Re-appointed on 08 April 2023
Ms. Nguyen Hong Ngoc	Member	Re-appointed on 08 April 2023
Ms. Pham Hai Yen	Member	Appointed on 08 April 2023

The Board of Directors

Full name	Position	Appointing/re-appointing date
Mr. Nguyen Van Kha	General Director	Re-appointed on 08 April 2023
Ms. Pham Thi Bich Thuy	Deputy General Director	Appointed on 02 February 2018
Mr. Lam Tri Hien	Deputy General Director	Appointed on 22 February 2019
Mr. Vu Minh Tuan	Deputy General Director	Appointed on 01 October 2019
Mr. Huynh Hoang Ha	Deputy General Director	Appointed on 01 January 2021

Legal Representative

The Company's legal representative during the period and as of the date of this statement is Mr. Nguyen Van Kha – General Director (re-appointed on 08 April 2023).

Auditors

A&C Auditing and Consulting Co., Ltd. has been appointed to perform the review on the Company's Interim Financial Statements for the first 6 months of the fiscal year ending 31 December 2025.

Responsibilities of the Board of Directors

The Company's Board of Directors is responsible for the preparation of the Interim Financial Statements to give a true and fair view of the financial position, the financial performance and the cash flows of the Company during the period. In order to prepare these Interim Financial Statements, the Board of Directors must:

- Select appropriate accounting policies and apply them consistently;
- Make judgments and estimates reasonably and prudently;
- State clearly whether the accounting standards applied to the Company are followed or not, and all the material differences from these standards are disclosed and explained in the Interim Financial Statements;
- Prepare the Interim Financial Statements of the Company on the going-concern basis, except for the cases that the going-concern assumption is considered inappropriate;
- Design and implement effectively the internal control system to minimize the risks of material misstatements due to frauds or errors in the preparation and presentation of the Interim Financial Statements.

The Board of Directors hereby ensures that all the proper accounting books of the Company have been fully recorded and can fairly reflect the financial position of the Company at any time, and that all the accounting books have been prepared in compliance with the applicable Accounting System. The Board of Directors is also responsible for managing the Company's assets and consequently has taken appropriate measures to prevent and detect frauds and other irregularities.

The Board of Directors hereby commits to the compliance with the aforementioned requirements in preparation of the Interim Financial Statements.

Approval of the Financial Statement

The Board of Management hereby approves the accompanying Interim Financial Statements which give a true and fair view of the financial position as of 30 June 2025 of the Company, its financial performance and its cash flows for the first 6 months of the fiscal year ending 31 December 2025, in conformity with the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY
STATEMENT OF THE BOARD OF MANAGEMENT (cont.)

and relevant statutory requirements on the preparation and presentation of the Interim Financial Statements.

For and on behalf of the Board of Management,



Phạm Phi Bích Thuy
Chairwoman

Date: 06 August 2025

A&C AUDITING AND CONSULTING CO., LTD.

Head Office : 02 Trương Sơn St., Tân Bình Dist., Ho Chi Minh City, Vietnam
Branch in Ha Noi : 40 Giảng Võ St., Đống Đa Dist., Hà Nội City, Vietnam
Branch in Nha Trang : Lot STH 06A/D1, St. No.13, Lê Hồng Phong II Urban Area, Nha Trang City, Vietnam
Branch in Can Tho : 15-13 Võ Nguyên Giáp St., Cái Rang Dist., Cần Thơ City, Vietnam

Tel: +84 (028) 3547 2972 kttv@a-c.com.vn
Tel: +84 (024) 3736 7879 kttv.hn@a-c.com.vn
Tel: +84 (0258) 246 5151 kttv.nt@a-c.com.vn
Tel: +84 (0292) 376 4995 kttv.ct@a-c.com.vn



www.a-c.com.vn

No: 4.0224/25/TC-AC

REPORT ON THE REVIEW OF INTERIM FINANCIAL INFORMATION

**To: THE SHAREHOLDERS, THE BOARD OF MANAGEMENT AND THE BOARD OF DIRECTORS
AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

We have reviewed the accompanying Interim Financial Statements of Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company"), which were prepared on 06 August 2025, from page 06 to page 42, including the Interim Balance Sheet as of 30 June 2025, the Interim Income Statement, the Interim Cash Flow Statement for the first 6 months of the fiscal year ending 31 December 2025 and the Notes to the Interim Financial Statements.

Responsibility of the Board of Directors

The Company's Board of Directors is responsible for the preparation, true and fair presentation of these Interim Financial Statements in accordance with the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System and relevant statutory requirements on the preparation and presentation of the Interim Financial Statements; and responsible for such internal control as the Company's Board of Directors determines necessary to enable the preparation and presentation of the Interim Financial Statements to be free from material misstatement due to frauds or errors.

Responsibility of Auditors

Our responsibility is to express conclusion on these Interim Financial Statements based on our review. We have conducted the review in accordance with the Vietnamese Standard on Review Engagements No. 2410 – Review on interim financial information performed by independent auditor of the entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion of Auditors

Based on our review, nothing has come to our attention that causes us to believe that the accompanying Interim Financial Statements have not given a true and fair view, in all material respects, of the financial position as of 30 June 2025 of the Company, its financial performance and its cash flows for the first 6 months of the fiscal year ending 31 December 2025, in conformity with the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System and relevant statutory requirements on the preparation and presentation of the Interim Financial Statements.



Nguyễn Hữu Danh

Partner

Audit Practice Registration Certificate No. 1242-2023-008-1

Authorized Signatory

Can Tho City, 06 August 2025

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

INTERIM BALANCE SHEET

(Full form)

As of 30 June 2025

Unit: VND

ITEMS	Code	Note	Ending balance	Beginning balance
A - CURRENT ASSETS	100		699.326.614.245	609.778.715.709
I. Cash and cash equivalents	110		32.147.789.280	13.948.008.363
1. Cash	111	V.1	32.147.789.280	13.948.008.363
2. Cash equivalents	112		-	-
II. Short-term financial investments	120		6.097.651.256	6.097.651.256
1. Trading securities	121	V.2a	1.097.651.256	1.097.651.256
2. Provisions for devaluation of trading securities	122		-	-
3. Held-to-maturity investments	123	V.2b	5.000.000.000	5.000.000.000
III. Short-term receivables	130		272.486.700.481	258.783.146.773
1. Short-term trade receivables	131	V.3	170.442.893.051	179.484.989.939
2. Short-term prepayments to suppliers	132	V.4	36.066.823.833	11.395.809.469
3. Short-term inter-company receivables	133		-	-
Receivable according to the progress of construction				
4. contract	134		-	-
5. Receivables for short-term loans	135		-	-
6. Other short-term receivables	136	V.5a	70.630.202.470	72.277.704.717
7. Allowance for short-term doubtful debts	137	V.6	(4.653.218.873)	(4.375.357.352)
8. Deficit assets for treatment	139		-	-
IV. Inventories	140		362.405.497.892	308.381.483.918
1. Inventories	141	V.7	362.405.497.892	308.381.483.918
2. Allowance for devaluation of inventories	149		-	-
V. Other current assets	150		26.188.975.336	22.568.425.399
1. Short-term prepaid expenses	151	V.8a	1.368.920.675	521.868.117
2. Deductible VAT	152		24.815.398.570	22.046.557.282
3. Taxes and other receivables from the State	153	V.15	4.656.091	-
4. Trading Government bonds	154		-	-
5. Other current assets	155		-	-

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Interim Balance Sheet (cont.)

ITEMS	Code	Note	Ending balance	Beginning balance
B- NON-CURRENT ASSETS	200		516.232.664.501	484.500.169.796
I. Long-term receivables	210		4.405.124.855	4.954.484.111
1. Long-term trade receivables	211		-	-
2. Long-term prepayments to suppliers	212		-	-
3. Working capital in affiliates	213		-	-
4. Long-term inter-company receivable	214		-	-
5. Receivables for long-term loans	215		-	-
6. Other long-term receivables	216	V.5b	4.405.124.855	4.954.484.111
7. Allowance for long-term doubtful debts	219		-	-
II. Fixed assets	220		393.040.609.072	409.569.275.905
1. Tangible fixed assets	221	V.9	323.113.950.041	332.661.038.753
- Historical cost	222		471.324.866.990	467.835.369.452
- Accumulated depreciation	223		(148.210.916.949)	(135.174.330.699)
2. Financial leased assets	224	V.10	51.759.640.616	55.314.565.893
- Historical cost	225		72.352.520.821	72.153.583.937
- Accumulated depreciation	226		(20.592.880.205)	(16.839.018.044)
3. Intangible fixed assets	227	V.11	18.167.018.415	21.593.671.259
- Initial cost	228		20.510.164.376	23.918.228.698
- Accumulated amortization	229		(2.343.145.961)	(2.324.557.439)
III. Investment property	230		-	-
- Historical costs	231		-	-
- Accumulated depreciation	232		-	-
IV. Long-term assets in process	240		95.134.681.500	47.427.697.783
1. Long-term work in process	241		-	-
2. Construction-in-progress	242	V.12	95.134.681.500	47.427.697.783
V. Long-term financial investments	250		17.130.750.000	17.130.750.000
1. Investments in subsidiaries	251		-	-
2. Investments in joint ventures and associates	252	V.2c	17.130.750.000	17.130.750.000
3. Investments in other entities	253		-	-
Provisions for devaluation of long-term financial				
4. investments	254		-	-
5. Held-to-maturity investments	255		-	-
VI. Other non-current assets	260		6.521.499.074	5.417.961.997
1. Long-term prepaid expenses	261	V.8b	6.521.499.074	5.417.961.997
2. Deferred income tax assets	262		-	-
3. Long-term components and spare parts	263		-	-
4. Other non-current assets	268		-	-
TOTAL ASSETS	270		1.215.559.278.746	1.094.278.885.505

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Interim Balance Sheet (cont.)

ITEMS	Code	Note	Ending balance	Beginning balance
C - LIABILITIES	300		786.420.911.138	694.419.479.026
I. Current liabilities	310		681.779.027.460	575.850.059.614
1. Short-term trade payables	311	V.13	123.833.225.411	116.186.090.928
2. Short-term advances from customers	312	V.14	6.574.252.885	5.840.952.759
3. Taxes and other obligations to the State Budget	313	V.15	5.844.145.025	11.518.187.495
4. Payables to employees	314		-	-
5. Short-term accrued expenses	315	V.16	521.116.956	1.013.603.826
6. Short-term inter-company payable	316		-	-
Payable according to the progress of construction				
7. contracts	317		-	-
8. Short-term unearned revenue	318	V.17	248.565.939	379.827.892
9. Other short-term payables	319	V.18	1.424.922.386	1.091.395.710
10. Short-term borrowings and financial leases	320	V.19a	528.885.008.174	422.757.402.847
11. Provisions for short-term payables	321		-	-
12. Bonus and welfare funds	322	V.20	14.447.790.684	17.062.598.157
13. Price stabilization fund	323		-	-
14. Trading Government bonds	324		-	-
II. Non-current liabilities	330		104.641.883.678	118.569.419.412
1. Long-term trade payables	331		-	-
2. Long-term advances from customers	332		-	-
3. Long-term accrued expenses	333		-	-
4. Inter-company payables for working capital	334		-	-
5. Long-term inter-company payables	335		-	-
6. Long-term unearned revenue	336		-	-
7. Other long-term payables	337		-	-
8. Long-term borrowings and financial leases	338	V.19b	104.641.883.678	118.569.419.412
9. Convertible bonds	339		-	-
10. Preferred shares	340		-	-
11. Deferred income tax liability	341		-	-
12. Provisions for long-term payables	342		-	-
13. Science and technology development fund	343		-	-

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Interim Balance Sheet (cont.)

ITEMS	Code	Note	Ending balance	Beginning balance
D - OWNER'S EQUITY	400		429.138.367.608	399.859.406.479
I. Owner's equity	410		429.138.367.608	399.859.406.479
1. Owner's capital	411	V.21a	266.152.680.000	231.439.410.000
- Ordinary shares carrying voting rights	411a		266.152.680.000	231.439.410.000
- Preferred shares	411b		-	-
2. Share premiums	412	V.21a	34.984.290.700	25.726.714.700
3. Bond conversion options	413		-	-
4. Other sources of capital	414		-	-
5. Treasury stocks	415		-	-
6. Differences on asset revaluation	416		-	-
7. Foreign exchange differences	417		-	-
8. Investment and development fund	418	V.21a	103.550.925.183	93.803.543.069
9. Business arrangement supporting fund	419		-	-
10. Other funds	420		-	-
11. Retained earnings	421	V.21a	24.450.471.725	48.889.738.710
- Retained earnings accumulated to the end of the previous period	421a		-	48.889.738.710
- Retained earnings of the current period	421b		24.450.471.725	-
12. Construction investment fund	422		-	-
II. Other sources and funds	430		-	-
1. Sources of expenditure	431		-	-
2. Fund to form fixed assets	432		-	-
TOTAL LIABILITIES AND OWNER'S EQUITY	440		1.215.559.278.746	1.094.278.885.505


Do Thi Kim Len
Preparer

Tran Nguyen Minh Hien
Chief Accountant

An Giang, 06 August 2025




Nguyen Van Kha
General Director

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

INTERIM INCOME STATEMENT

(Full form)

For the first 6 months of the fiscal year ending 31 December 2025

Unit: VND

ITEMS	Code	Note	year	
			Current year	Previous year
1. Revenue from sales of goods and provisions of services	01	VI.1	409.783.064.337	374.969.024.079
2. Revenue deductions	02	VI.2	1.857.624.031	3.960.245.676
3. Net revenue	10		407.925.440.306	371.008.778.403
4. Cost of sales	11	VI.3	291.752.118.991	265.982.938.952
5. Gross profit	20		116.173.321.315	105.025.839.451
6. Financial income	21	VI.4	274.353.608	258.754.611
7. Financial expenses	22	VI.5	20.856.576.319	15.836.773.867
In which: Loan interest expenses	23		18.880.133.246	14.217.692.368
8. Selling expenses	25	VI.6	46.914.133.258	42.619.903.826
9. General and administration expenses	26	VI.7	21.478.189.285	19.432.079.820
10. Net operating profit	30		27.198.776.061	27.395.836.549
11. Other income	31	VI.8	3.158.686.633	101.919.442
12. Other expenses	32	VI.9	115.000	296.558.708
13. Other profit/(loss)	40		3.158.571.633	(194.639.266)
14. Total accounting profit before tax	50		30.357.347.694	27.201.197.283
15. Current income tax	51	V.15	5.906.875.969	5.309.587.060
16. Deferred income tax	52		-	-
17. Profit after tax	60		24.450.471.725	21.891.610.223
18. Earnings per share	70	VI.10a,b	866	790
19. Diluted earnings per share	71	VI.10a,b	866	790


Do Thi Kim Len
Preparer

Tran Nguyen Minh Hien
Chief Accountant

An Giang, 06 August 2025

**CÔNG TY
CP
DƯỢC PHẨM
AGIMEXPHARM**

TP. LONG XUYEN - T. AN GIANG



Nguyen Van Kha
General Director

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

INTERIM CASH FLOW STATEMENT

(Full form)

(Indirect method)

For the first 6 months of the fiscal year ending 31 December 2025

Unit: VND

ITEMS	Code	Note	Accumulated from the beginning of the year	
			Current year	Previous year
I. Cash flows from operating activities				
1. Profit before tax	01		30.357.347.694	27.201.197.283
2. Adjustments				
- Depreciation/Amortization of fixed assets and investment properties	02	V.9, V.10, V.11	18.433.774.920	16.303.533.395
- Provisions and allowances	03	V.6	277.861.521	87.494.970
- Exchange gain/(loss) due to revaluation of monetary items in foreign currencies	04	VI.5	330.989.924	37.966.282
- Gain/(loss) from investing activities	05	VI.4, VI.9	(2.873.454.392)	19.711.276
- Interest expenses	06	VI.5	18.880.133.246	14.217.692.368
- Others	07		-	-
3. Operating profit before changes of working capital	08		65.406.652.913	57.867.595.574
- Increase/(decrease) of receivables	09		3.545.851.030	(41.840.485.922)
- Increase/(decrease) of inventories	10		(54.024.013.974)	7.507.232.133
- Increase/(decrease) of payables	11		8.576.455.329	(13.892.727.621)
- Increase/(decrease) of prepaid expenses	12		(1.935.457.635)	(1.097.703.258)
- Increase/(decrease) of trading securities	13		-	-
- Interests paid	14	V.16, VI.5	(18.914.083.482)	(14.186.406.241)
- Corporate income tax paid	15	V.15	(11.722.011.234)	(10.582.967.422)
- Other cash inflows	16		-	-
- Other cash outflows	17		(7.043.893.569)	(3.756.505.965)
Net cash flows from operating activities	20		(16.110.500.622)	(19.981.968.722)
II. Cash flows from investing activities				
1. Purchases and construction of fixed assets and other long-term assets	21	V.4, V.13, V.9, V.10, V.12	(76.395.909.620)	(76.003.587.401)
2. Proceeds from disposals of fixed assets and other long-term assets	22		9.010.746.737	3.124.545.455
3. Cash outflow for lending, buying debt instruments of other entities	23		-	(7.501.265.000)
4. Cash recovered from lending, selling debt instruments of other entities	24		-	-
5. Investments into other entities	25		-	-
6. Withdrawals of investments in other entities	26		-	-
7. Interest earned, dividends and profits received	27		-	2.374.500
Net cash flows from investing activities	30		(67.385.162.883)	(80.377.932.446)

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Interim Cash Flow Statement (cont.)

ITEMS	Code	Note	Accumulated from the beginning of the year	
			Current year	Previous year
III. Cash flows from financing activities				
1. Proceeds from issuing stocks and capital contributions from owners	31	V.21a	20.829.546.000	-
2. Repayment for capital contributions and re-purchases of stocks already issued	32		-	-
3. Proceeds from borrowings	33	V.19a,b	388.120.415.179	367.430.423.521
4. Repayment for loan principal	34	V.19a	(285.313.193.660)	(260.093.223.492)
5. Payments for financial leased assets	35	V.19a,b	(10.607.151.926)	(9.160.126.141)
6. Dividends and profit paid to the owners	36	V.21d	(11.343.723.000)	(401.175.020)
Net cash flows from financing activities	40		101.685.892.593	97.775.898.868
Net cash flows during the period	50		18.190.229.088	(2.584.002.300)
Beginning cash and cash equivalents	60	V.1	13.948.008.363	28.593.912.944
Effects of fluctuations in foreign exchange rates	61		9.551.829	8.698.504
Ending cash and cash equivalents	70	V.1	32.147.789.280	26.018.609.148



An Giang, 06 August 2025

Do Thi Kim Len
Preparer

Tran Nguyen Minh Hien
Chief Accountant

Nguyen Van Kha
General Director

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

I. GENERAL INFORMATION**1. Ownership form**

Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as “the Company”) is a joint stock company.

2. Operating field

The Company’s operating fields are industrial production and trading.

3. Principal business activities

Principal business activities of the Company are to manufacture medicines, pharmaceutical chemicals and pharmaceutical materials; trade optical, medical, dental and hospital equipment; trade medicines, pharmaceutical products; trade nutritious food; produce and trade cosmetics; trade materials and ancillary materials, pharmaceutical chemicals for pharmaceutical production; trade vaccines and medical biological products; manufacture bottled water (the Company must comply with the Law on food safety and hygiene during operation course); manufacture dietary supplements; manufacture, trade and process essential oil from herbs; manufacture and trade food, nutritious food and dietary supplements.

4. Normal operating cycle

Normal operating cycle of the Company is within 12 months.

5. Structure of the Company***Joint venture***

The Company only invests in USA-AGP Pharma, LLC headquartered at No. 14314 Brookhurst Street, Graden Grove City, California, 92843. Principal business activities of this joint venture are to package and trade bottled capsules and tablets of dietary supplements, pharmaceutical products, ganoderma, cordyceps. As of the balance sheet date, the Company’s capital contribution rate at this joint venture is 43,24%, equivalent to the voting rate and ownership rate.

6. Statement of information comparability on the Interim Financial Statements

The corresponding figures in the previous period can be comparable with figures in the current period.

7. Headcount

As of the balance sheet date, the Company’s headcount is 478 (headcount at the beginning of the year: 490).

II. FISCAL YEAR AND ACCOUNTING CURRENCY**1. Fiscal year**

The fiscal year of the Company is from 01 January to 31 December annually.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

2. Accounting currency unit

The accounting currency unit is Vietnamese Dong (VND) because the Company's transactions are primarily made in VND.

III. ACCOUNTING STANDARDS AND SYSTEM

1. Accounting System

The Company applies the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System, which were issued together with the Circular No. 200/2014/TT-BTC dated 22 December 2014, the Circular No. 53/2016/TT-BTC dated 21 March 2016 as well as other Circulars guiding the implementation of Vietnamese Accounting Standards of the Ministry of Finance in the preparation and presentation of Interim Financial Statements.

2. Statement of the compliance with the Accounting Standards and System

The Board of Directors ensures to follow all the requirements of the Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting System, which were issued together with the Circular No. 200/2014/TT-BTC dated 22 December 2014, the Circular No. 53/2016/TT-BTC dated 21 March 2016 as well as other Circulars guiding the implementation of Vietnamese Accounting Standards of the Ministry of Finance in the preparation and presentation of the Interim Financial Statements.

IV. ACCOUNTING POLICIES

1. Accounting convention

All the Financial Statements are prepared on the accrual basis (except for the information related to cash flows).

2. Foreign currency transactions

Transactions in foreign currencies are converted at the actual exchange rates ruling as of the transaction dates. The ending balances of monetary items in foreign currencies are converted at the actual exchange rates ruling as of the balance sheet date.

Foreign exchange differences arisen from foreign currency transactions during the period shall be included into financial income or financial expenses. Foreign exchange differences due to the revaluation of ending balances of the monetary items in foreign currencies after offsetting their positive differences against negative differences shall be included into financial income or financial expenses.

The exchange rate used to convert foreign currency transactions is the actual exchange rate ruling as at the time of these transactions. The actual exchange rates applied to foreign currency transactions are as follows:

- For the foreign currency trading contract (including spot contract, forward contract, future contract, option contract, currency swap): the exchange rate stipulated in the contracts of trading foreign currency between the Company and the Bank.
- For receivables: the buying rate ruling as at the time of transaction of the commercial bank where the Company designates the customers to make payments.
- For payables: the selling rate ruling as at the time of transaction of the commercial bank where the Company supposes to make payments.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

- For acquisition of assets or immediate payments in foreign currency (not included into payable accounts): the buying rate of the commercial bank where the Company makes payments.

The exchange rates used to re-evaluate the ending balances of monetary items in foreign currencies are determined according to the following principles:

- For foreign currency deposits: the buying rate of the bank where the Company opens its foreign currency account.
- For monetary items in foreign currencies classified as other assets: the buying rate of Vietnam Joint Stock Commercial Bank for Industry and Trade (VietinBank) - An Giang Branch, where the Company frequently conducts transactions.
- For monetary items in foreign currencies classified as liabilities: the selling rate of Vietnam Joint Stock Commercial Bank for Industry and Trade (VietinBank) - An Giang Branch, where the Company frequently conducts transactions.

3. Cash

Cash includes cash on hand and demand deposits.

4. Financial investments

Trading securities

Investments classified as trading securities are those held by the Company for the trading purpose with the aim of making profit.

Trading securities are recognized at costs which include fair value of the payments made at the time of the transaction plus other costs attributable to transaction costs.

The time of recognizing trading securities is when the Company acquires the ownership, as follows:

- For listed securities: recognized at the time of order-matching (T+0).
- For unlisted securities: recognized at the time of acquiring official ownership as stipulated by law.

Interest, dividends, and profit of the periods prior to the acquisition of trading securities are recorded as a decrease in the value of such securities. Interest, dividends and profit of the periods after the acquisition of such securities are recorded in the Company's revenues.

Provisions for devaluation of trading securities are made for each particular type of securities in the market of which the fair value is lower than original costs. The fair value of the shares is determined as follows:

- For securities listed on the stock market: the closing price at the most recent trading date by the balance sheet date.
- For shares registered for trading on UPCOM and those of State-owned enterprises equitized in form of public offering: the average reference price in the 30 most preceding trading days prior to the balance sheet date, disclosed by Stock Exchange.
- For shares listed on the stock market or shares registered for trading on Upcom without transactions within 30 days prior to the date of provision, the shares which are delisted, canceled or suspended from trading: provision is made based on the losses of the investee at the rate equal to the difference between the actual capital invested by the owners and owner's equity as of the balance sheet date multiplying by the Company's ownership rate of charter capital over the total actual charter capital invested.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

Increases/decreases in the provisions for devaluation of trading securities as of the balance sheet date are recorded into financial expenses.

Gain or loss from transfer of trading securities is recognized into financial income or financial expenses. The costs are determined in accordance with the mobile weighted average method.

Held-to-maturity investments

Investments are classified as held-to-maturity investments that the Company intends and is able to hold to maturity. Held-to-maturity investments include term deposits and bonds for the purpose of receiving periodical interest.

Held-to-maturity investments are initially recognized at cost including the purchase cost and other transaction costs. After initial recognition, these investments are recorded at recoverable value. Interest from these held-to-maturity investments after acquisition date is recognized in the profit or loss on the basis of the interest income to be received. Interests arising prior to the Company's acquisition of held-to-maturity investments are recorded as a decrease in the costs as at the acquisition time.

When there are reliable evidences proving that a part or the whole investment cannot be recovered and the loss is reliably determined, the loss is recognized as financial expenses during the period while the investment value is derecognized.

Investments in joint venture

Joint venture

A joint venture is an entity which is established by a contractual arrangement whereby the Company and the involved parties undertake an economic activity that is subject to joint control. Joint control is the contractually agreed sharing of control over an economic activity, and exists only when the strategic financial and operating decisions relating to the activity require the unanimous consent of the venturers.

Initial recognition

Investments in joint venture are initially recognized at costs, including the cost of purchase or capital contributions plus other directly attributable transaction cost. In case of investment in non-monetary assets, the costs of the investment are recognized at the fair value of non-monetary assets at the arising time.

Dividends and profits of the periods prior to the purchase of investments are recorded as a decrease in value of such investments. Dividends and profit of the periods after the purchase of investments are recorded into the Company's revenues.

Provisions for impairment of investments in joint venture

Provisions for impairment of investments in joint venture are made when the joint venture suffers from losses at the rate equal to the difference between the actual capital invested by investors in joint venture and the actual owner's equity multiplying (x) by the ownership rate of the charter capital actually contributed by the Company in the joint venture. If the joint venture is consolidated into Consolidated Financial Statements, the basis for impairment provisions is the Consolidated Financial Statements.

Increases/decreases in the provisions for impairment of investments in joint venture as of the balance sheet date are recorded into financial expenses.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

5. Receivables

Receivables are recognized at the carrying amounts less allowances for doubtful debts.

The classification of receivables as trade receivables and other receivables is made according the following principles:

- Trade receivables reflect receivables concerning the commercial nature arising from purchase and sale transactions between the Company and customers who are independent to the Company.
- Other receivables reflect receivables not concerning the commercial nature and irrelevant to purchase and sale transactions.

Allowance is made for each doubtful debt on the basis of estimated loss.

Increases/decreases in the obligatory allowance for doubtful debts as of the balance sheet date are recorded into general and administration expenses.

6. Inventories

Inventories are recognized at the lower of cost or net realizable value.

Cost of inventories is determined as follows:

- For materials and merchandise: Costs comprise costs of purchases and other directly relevant costs incurred in bringing the inventories to their present location and conditions.
- Work-in-process: Costs comprise costs of main materials, labor and other directly relevant costs.
- For finished goods: Costs comprise costs of materials, direct labor and directly relevant general manufacturing expenses allocated on the basis of normal operations.

Stock-out costs are determined in accordance with the weighted average method and recorded in line with the perpetual method.

Net realizable value is the estimated selling price of inventories in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Allowance for devaluation of inventories is recognized for each type of inventory when its cost is higher than its net realizable value. Increases/(decreases) in the allowance for devaluation of inventories required to be made as of the fiscal year-ended are recorded into "Cost of sales."

7. Prepaid expenses

Prepaid expenses comprise actual expenses incurred and relevant to financial performance in several accounting periods. Prepaid expenses of the Company mainly include:

Tools

Expenses of tools being put into use are allocated into costs in accordance with the straight-line method for the maximum period of 3 years.

Expenses of fixed asset repairs

Expenses of fixed asset repairs incurred once with high value are allocated into costs in accordance with the straight-line method in 3 years.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

8. Tangible fixed assets

Tangible fixed assets are determined by their historical costs less accumulated depreciation. Historical costs of tangible fixed assets include all the expenses paid by the Company to bring the asset to its working condition for its intended use. Other expenses arising subsequent to initial recognition are included into historical costs of fixed assets only if it can be clearly demonstrated that the expenditure has resulted in future economic benefits expected to be obtained from the use of these assets. Those which do not meet the above conditions will be recorded into operation costs during the period.

When a tangible fixed asset is sold or disposed, its historical cost and accumulated depreciation are written off, then any gain or loss arising from such disposal is included in the income or the expenses during the period.

Tangible fixed assets are depreciated in accordance with the straight-line method over their estimated useful lives. The depreciation years applied are as follows:

<u>Fixed assets</u>	<u>Years</u>
Buildings and structures	05 – 25
Machinery and equipment	02 – 15
Vehicles	05 – 10
Office equipment	03 – 10

9. Financial leased assets

A lease is classified as a finance lease if it transfers substantially all the risks and rewards incident to ownership belonging to the lessee. Financial leased assets are determined by their historical costs less accumulated depreciation. Historical cost is the lower cost of the fair value of the leased asset at commencement of the lease term and the present value of the minimum lease payments. Discount rate used to calculate the present value of the minimum lease payments is the interest rate implicit in the lease or else mentioned in the lease. If the interest rate implicit in the lease cannot be determined, the incremental borrowing rate at commencement of the lease term will be applied.

Financial leased assets are depreciated in accordance with the straight-line method over their estimated useful lives. If there is no reasonable certainty that the Company will obtain ownership at the end of the lease, the fixed asset shall be depreciated over the shorter of the lease term and the estimated useful life of the asset. The depreciation years of the financial leased assets are as follows:

<u>Fixed assets</u>	<u>Years</u>
Machinery and equipment	03 – 15

10. Intangible fixed assets

Intangible fixed assets are determined by their initial costs less accumulated amortization.

Initial costs of intangible fixed assets include all the costs paid by the Company to bring the asset to its working condition for its intended use. Other costs relevant to intangible fixed assets arising subsequent to initial recognition are included into operation costs during the period only if these costs are associated with a specific intangible fixed asset and result in future economic benefits expected to be obtained from the use of these assets.

When an intangible fixed asset is sold or disposed, its initial costs and accumulated amortization are written off, then any gain or loss arising from such disposal is included in the income or the expenses during the period.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

The Company's intangible fixed assets include:

Land use right

Land use right includes all the actual expenses paid by the Company directly related to the land being used such as expenses to obtain the land use right, expenses for house removal, land clearance and ground leveling, registration fees, etc. The land use right is amortized in accordance with the straight-line method over the term specified in the land use right certificate. If the land use right is permanent, it is not amortized.

Computer software

Expenses attributable to computer software, which is not a part associated with the relevant hardware, will be capitalized. Costs of computer software include all the expenses paid by the Company until the date the software is put into use. Computer software is amortized in accordance with the straight-line method in 10 years.

11. Construction-in-progress

Construction-in-progress reflects the expenses (including relevant loan interest expenses following the accounting policies of the Company) directly related to assets under construction and machinery and equipment under installation to serve for production, leasing, and management as well as the repair of fixed assets in progress. These assets are recorded at historical costs and not depreciated.

12. Payables and accrued expenses

Payables and accrued expenses are recorded for the amounts payable in the future associated with the goods and services received. Accrued expenses are recorded based on reasonable estimates for the amounts payable.

The classification of payables as trade payables, accrued expenses and other payables is made on the basis of following principles:

- Trade payables reflect payables of commercial nature arising from the purchase of goods, services, or assets, of which the seller is an independent entity with the Company.
- Accrued expenses reflect expenses for goods, services received from suppliers or supplied to customers but have not been paid, invoiced or lack of accounting records and supporting documents; pay on leave payable to employees; and accrual of operation expenses.
- Other payables reflect payables of non-commercial nature and irrelevant to purchase, sales of goods or provisions of services.

The payables and accrued expenses are classified as short-term and long-term items in the Interim Balance Sheet on the basis of their remaining term as of the balance sheet date.

13. Owner's equity***Owner's capital***

The owner's capital is recorded according to the actual amounts contributed by shareholders.

Share premiums

Share premiums are recorded in accordance with the difference between the issuance price and face value upon the IPO, additional issue or the difference between the re-issuance price and carrying value of treasury shares and the equity component of convertible bonds upon maturity

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

date. Expenses directly related to the additional issue of shares and the re-issuance of treasury shares are recorded as a decrease in share premiums.

14. Profit distribution

Profit after tax is distributed to the shareholders after appropriation for funds under the Charter of the Company as well as legal regulations and approved by the General Meeting of Shareholders.

The distribution of profits to the shareholders is made with consideration toward non-cash items in the retained earnings that may affect cash flows and payment of dividends such as profit due to revaluation of assets contributed as investment capital, profit due to revaluation of monetary items, financial instruments and other non-cash items.

Dividends are recorded as payables upon approval of the General Meeting of Shareholders.

15. Recognition of revenue and income

Revenue from sales of merchandise, finished goods

Revenue from sales of merchandise, finished goods shall be recognized when all of the following conditions are satisfied:

- The Company transfers most of risks and benefits incident to the ownership of products or merchandises to customers.
- The Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the merchandise, products sold.
- The amount of revenue can be measured reliably. When the contracts stipulate that buyers have the right to return merchandise, products purchased under specific conditions, the revenue is recorded only when those specific conditions are no longer exist and buyers retains no right to return products (except for the case that such returns are in exchange for other merchandise or services).
- The Company received or shall probably receive the economic benefits associated with sale transactions.
- The cost incurred or to be incurred in respect of the sale transaction can be measured reliably.

Interest

Interest is recorded, based on the term and the actual interest rate applied in each particular period.

Dividends and profit shared

Dividends and profit shared are recognized when the Company has the right to receive dividends or profit from the capital contribution. Particularly, the dividends paid in form of shares are not recorded as an increase in value, but the increasing quantity is followed up.

16. Revenue deductions

Revenue deductions include trade discounts, sales allowances, sales returns incurred in the same period of providing products, merchandises, in which revenues are derecognized.

In case of products, merchandise provided in the previous periods but trade discounts, sales allowances, sales returns incurred in the current period, revenues are derecognized as follows:

- If sales allowances, trade discounts, sales returns incur prior to the release of the Interim Financial Statements, revenues are derecognized on the Interim Financial Statements of the current period.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

- If sales allowances, trade discounts, sales returns incur after the release of the Interim Financial Statements, revenues are derecognized on the Interim Financial Statements of the following period.

17. Borrowing costs

Borrowing costs are interests and other costs that the Company directly incurs in connection with the borrowing.

Borrowing costs are recorded as an expense when it is incurred. In case the borrowing costs are directly attributable to the construction or the production of an asset in progress, which takes a substantial period of time (over 12 months) to get ready for intended use or sales of the asset, these costs will be included in the cost of that asset. To the extent that the borrowings are especially for the purpose of construction of fixed assets and investment properties, the borrowing cost is eligible for capitalization even if construction period is under 12 months. Incomes arisen from provisional investments as loans are recognized as a decrease in the costs of relevant assets.

In the event that general borrowings are partly used for the acquisition, construction or production of an asset in progress, the costs eligible for capitalization will be determined by applying the capitalization rate to average accumulated expenditure on construction or production of that asset. The capitalization rate is computed at the weighted average interest rate of the borrowings not yet paid during the period, except for particular borrowings serving the purpose of obtaining a specific asset.

18. Expenses

Expenses are those that result in outflows of the Company's economic benefits and are recorded at the time of transactions or when incurrence of the transaction is reliable regardless of whether payment for expenses is made or not.

Expenses and their corresponding revenues are simultaneously recognized in accordance with matching principle. In the event that matching principle conflicts with prudence principle, expenses are recognized based on the nature and regulations of accounting standards in order to guarantee that transactions can be fairly and truly reflected.

19. Corporate income tax

Corporate income tax includes current income tax and deferred income tax.

Current income tax

Current income tax is the tax amount computed based on the taxable income. Taxable income is different from accounting profit due to the adjustments of temporary differences between tax and accounting figures, non-deductible expenses as well as those of non-taxable income and losses brought forward.

Deferred income tax

Deferred income tax is the amount of corporate income tax payable or refundable due to temporary differences between book values of assets and liabilities serving the preparation of the Financial Statements and the values for tax purposes. Deferred income tax liabilities are recognized for all the temporary taxable differences. Deferred income tax assets are recorded only when there is an assurance on the availability of taxable income in the future against which the temporarily deductible differences can be used.

Carrying values of deferred corporate income tax assets are considered as of the balance sheet date and will be reduced to the rate that ensures enough taxable income against which the benefits from

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

part of or all of the deferred income tax can be used. Deferred corporate income tax assets, which have not been recorded before, are considered as of the balance sheet date and are recorded when there is certainly enough taxable income to use these unrecognized deferred corporate income tax assets.

Deferred income tax assets and deferred income tax liabilities are determined at the estimated rate to be applied in the year when the assets are recovered or the liabilities are settled based on the effective tax rates as of the balance sheet date. Deferred income tax is recognized in the Income Statement. In the case that deferred income tax is related to the items of the owner's equity, corporate income tax will be included in the owner's equity.

The Company shall offset deferred tax assets and deferred tax liabilities if:

- The Company has the legal right to offset current income tax assets against current income tax liabilities; and
- Deferred income tax assets and deferred income tax liabilities are relevant to corporate income tax which is under the management of one tax authority either:
 - Of the same subject to corporate income tax; or
 - The Company has intention to pay current income tax liabilities and current income tax assets on a net basis or recover tax assets and settle tax liability simultaneously in each future period to the extent that the majority of deferred income tax liabilities or deferred income tax assets are paid or recovered.

20. Related parties

A party is considered a related party of the Company in case that party is able to control the Company or to cause material effects on the financial decisions as well as the operations of the Company. A party is also considered a related party of the Company in case that party is under the same control or is subject to the same material effects.

Considering the relationship of related parties, the nature of relationship is focused more than its legal form.

21. Segment reporting

A business segment is a distinguishable component of the Company that is engaged in manufacturing or providing products or services and that is subject to risks and returns that are different from those of other business segments.

A geographical segment is a distinguishable component of the Company that is engaged in manufacturing or providing products or services within a particular economic environment and that is subject to risks and returns that are different from those of components operating in other economic environments.

Segment information is prepared and presented in compliance with the accounting policy in the preparation and presentation of the Interim Financial Statements of the Company.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)**V. ADDITIONAL INFORMATION ON THE ITEMS OF THE INTERIM BALANCE SHEET****1. Cash**

	Ending balance	Beginning balance
Cash on hand	13.966.991.607	4.791.483.403
Demand deposits	18.180.797.673	9.156.524.960
Total	32.147.789.280	13.948.008.363

2. Financial investments

The financial investments of the Company include trading securities, held-to-maturity investments and investments in other entities. The Company's financial investments are as follows:

2a. Trading securities

	Ending balance			Beginning balance		
	Original amount	Fair value	Provision	Original amount	Fair value	Provision
Shares						
Imexpharm Corporation	1.052.350.306	8.159.817.600	-	1.052.350.306	7.432.392.000	-
Mekophar Chemical Pharmaceutical Joint-Stock Company	45.300.950	138.670.800	-	45.300.950	135.346.500	-
Total	1.097.651.256	8.298.488.400	-	1.097.651.256	7.567.738.500	-

2b. Held-to-maturity investments

	Ending balance		Beginning balance	
	Original amount	Carrying value	Original amount	Carrying value
Short-term				
Deposits of which term is 12 months and the interest rate is 5,3%/year ⁽ⁱ⁾	5.000.000.000	5.000.000.000	5.000.000.000	5.000.000.000
Total	5.000.000.000	5.000.000.000	5.000.000.000	5.000.000.000

⁽ⁱ⁾ This deposits at Vietnam Joint Stock Commercial Bank for Industry and Trade (VietinBank) - An Giang Branch, have been mortgaged to secure the loans from Bank (see Note No. V.19a).

2c. Investments in other entities

	Ending balance		Beginning balance	
	Original amount	Provision	Original amount	Provision
Investments in joint venture				
USA-AGP Pharma, LLC ⁽ⁱ⁾	17.130.750.000	-	17.130.750.000	-
Total	17.130.750.000	-	17.130.750.000	-

⁽ⁱ⁾ According to the Investment Certificate No. 201900695, registered for the first time on 19 July 2019 and amended for the first time on 09 April 2022, granted by the Ministry of Planning and Investment, the Company invests an amount of VND 19.663.050.000 (USD 850.000) in USA-AGP Pharma, LLC, equivalent to 50% of charter capital. As of the balance sheet date, the Company

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

invested VND 17.130.750.000 (USD 735.000), equivalent to 43,24% of charter capital. The charter capital to be invested in USA-AGP Pharma, LLC is VND 2.532.300.000 (USD 115.000).

Fair value

Fair value of investments with listed price is measured at the listed price as of the balance sheet date. The Company has not measured the fair value of the investments without listed price because there is no specific instruction on measurement of fair value.

Operation of the joint venture

USA-AGP Pharma, LLC has completed the construction of Manufacturing Plant with the objectives as specified in the Overseas Investment Registration Certificate. Currently, the Company has completed all procedures and licenses to put this plant into operation.

Transactions with the joint venture

During the period, the Company sold goods to USA-AGP Pharma, LLC which is a joint venture for an amount of VND 716.327.070 (previous period: VND 201.871.420).

3. Short-term trade receivables

	<u>Ending balance</u>	<u>Beginning balance</u>
<i>Receivables from related parties</i>	3.316.853.855	962.864.189
Imexpharm Corporation	2.600.526.785	962.864.189
USA-AGP Pharma, LLC	716.327.070	-
<i>Receivables from other customers</i>	167.126.039.196	178.522.125.750
Tue Nam Pharmaceutical Co., Ltd.	5.912.374.378	8.745.623.271
Trans-Asia Hospital Investment Joint-Stock Company	9.868.114.198	8.931.091.099
Pharmacy Pharmacy Joint Stock Company	7.916.648.545	8.009.590.959
Nagomed Co., Ltd.	7.199.686.203	6.601.107.705
Other customers	136.229.215.872	146.234.712.716
Total	<u>170.442.893.051</u>	<u>179.484.989.939</u>

Some short-term trade receivables, of which any time of carrying value is VND 64.000.000.000, have been mortgaged to secure the loans from Vietnam Joint Stock Commercial Bank for Industry and Trade - An Giang Branch (see Note No. V.19a).

4. Short-term prepayments to suppliers

	<u>Ending balance</u>	<u>Beginning balance</u>
Khang Gia Design - Construction - Trading Company Limited	3.129.829.409	10.106.742.018
Truiking Technology Limited	17.245.524.000	-
Other suppliers	15.691.470.424	1.289.067.451
Total	<u>36.066.823.833</u>	<u>11.395.809.469</u>

	<u>Ending balance</u>	<u>Beginning balance</u>
<i>In which:</i>		
Short-term prepayments to suppliers for the acquisition of fixed assets/capital construction	30.521.952.708	10.873.072.018

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)**5. Other receivables****5a. Other short-term receivables**

	Ending balance		Beginning balance	
	Value	Allowance	Value	Allowance
Term deposit interest to be received	191.589.041	-	88.027.397	-
Advances	35.159.984.150	-	37.039.568.135	-
Short-term mortgages, deposits	33.080.467.805	-	32.297.027.947	-
Other short-term receivables	2.198.161.474	-	2.853.081.238	-
Total	70.630.202.470	-	72.277.704.717	-

5b. Other long-term receivables

This item reflects long-term mortgages and deposits.

6. Doubtful debts

	Ending balance		Beginning balance	
	Original amount	Recoverable amount	Original amount	Recoverable amount
Receivables from other organizations and individuals - <i>Trade receivables</i>	4.653.218.873	-	4.375.357.352	-
Total	4.653.218.873	-	4.375.357.352	-

Changes in allowances for short-term doubtful debts are as follows:

	Accumulated from the beginning of the year	
	Current year	Previous year
Beginning balance	4.375.357.352	4.348.862.382
Extraction for allowance	277.861.521	87.494.970
Ending balance	4.653.218.873	4.436.357.352

7. Inventories

	Ending balance		Beginning balance	
	Original costs	Allowance	Original costs	Allowance
Materials and supplies	193.500.852.769	-	158.690.608.803	-
Work-in-process	21.308.304.628	-	23.778.998.017	-
Finished goods	146.080.462.335	-	124.631.128.058	-
Merchandise	1.515.878.160	-	1.280.749.040	-
Total	362.405.497.892	-	308.381.483.918	-

Some inventories, of which the ending balance of carrying value is VND 238.000.000.000, have been mortgaged to secure the loans from Banks (see Note No. V.19a).

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)**8. Prepaid expenses****8a. Short-term prepaid expenses**

	<u>Ending balance</u>	<u>Beginning balance</u>
Expenses of tools	13.839.840	60.026.030
Expenses of factory design	638.957.143	-
Other short-term prepaid expenses	716.123.692	461.842.087
Total	<u>1.368.920.675</u>	<u>521.868.117</u>

8b. Long-term prepaid expenses

	<u>Ending balance</u>	<u>Beginning balance</u>
Expenses of tools	2.772.209.471	2.958.322.313
Expenses of fixed asset repairs	1.660.971.743	895.328.687
Other long-term prepaid expenses	2.088.317.860	1.564.310.997
Total	<u>6.521.499.074</u>	<u>5.417.961.997</u>

9. Tangible fixed assets

Increases/(decreases) of tangible fixed assets are presented in the attached Appendix 01.

Some tangible fixed assets, of which the carrying values are VND 277.924.149.531, have been mortgaged to secure the loans from Banks (see Notes No. V.19a and V.19b).

10. Financial leased assets

	<u>Machinery and equipment</u>
Historical costs	
Beginning balance	72.153.583.937
Increase during the period	2.845.931.867
Purchase during the period	(2.646.994.983)
Ending balance	<u>72.352.520.821</u>
Depreciation	
Beginning balance	16.839.018.044
Depreciation during the period	5.247.206.148
Purchase during the period	(1.493.343.987)
Ending balance	<u>20.592.880.205</u>
Carrying values	
Beginning balance	55.314.565.893
Ending balance	<u>51.759.640.616</u>

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

11. Intangible fixed assets

	Land use right	Computer software	Total
Initial costs			
Beginning balance	22.114.149.854	1.804.078.844	23.918.228.698
Disposal and liquidation	(3.408.064.322)	-	(3.408.064.322)
Ending balance	18.706.085.532	1.804.078.844	20.510.164.376
<i>In which:</i>			
Assets fully amortized but still in use	-	1.804.078.844	1.804.078.844
Assets waiting for liquidation	-	-	-
Amortization			
Beginning balance	520.478.595	1.804.078.844	2.324.557.439
Amortization during the period	18.588.522	-	18.588.522
Ending balance	539.067.117	1.804.078.844	2.343.145.961
Carrying values			
Beginning balance	21.593.671.259	-	21.593.671.259
Ending balance	18.167.018.415	-	18.167.018.415
<i>In which:</i>			
Assets temporarily not in use	-	-	-
Assets waiting for liquidation	-	-	-

All land use rights, of which the carrying values are VND 18.167.018.415, has been mortgaged to secure the loans from Banks (see Note No. V.19a).

12. Construction-in-progress

	Beginning balance	Increase during the period	Inclusion into fixed assets during the period	Ending balance
Acquisition of fixed assets	9.800.000.000	-	-	9.800.000.000
Construction-in-progress	37.627.697.783	48.169.588.717	(462.605.000)	85.334.681.500
- Construction of liquid medicine plant	16.744.234.609	32.877.382.223	-	49.621.616.832
- Expansion of pharmaceutical plant	3.545.018.862	7.466.759.883	-	11.011.778.745
- Other works	17.338.444.312	7.825.446.611	(462.605.000)	24.701.285.923
Total	47.427.697.783	48.169.588.717	(462.605.000)	95.134.681.500

13. Short-term trade payable

	Ending balance	Beginning balance
Payables to related party	6.420.139.623	2.651.071.764
Imexpharm Corporation	6.420.139.623	2.651.071.764
Payables to other suppliers	117.413.085.788	113.535.019.164
Branch of Glandcore Company Limited	14.380.500.782	13.660.348.610
Phuong Phuc Pharmaceutical Chemical Company Limited	21.878.013.221	22.197.386.999
Other suppliers	81.154.571.785	77.677.283.555
Total	123.833.225.411	116.186.090.928

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

	<u>Số cuối kỳ</u>	<u>Số đầu năm</u>
<i>In which:</i>		
Short-term prepayments to suppliers for the acquisition of fixed assets/capital construction	550.598.632	1.429.549.769

The Company has no overdue trade payables.

14. Short-term advances from customers

	<u>Ending balance</u>	<u>Beginning balance</u>
Thien Dien Pharmaceutical Joint Stock Company	2.751.950.245	2.999.999.997
Ms. Le Bich Ngoc	665.041.069	649.032.372
Duke University	1.144.302.300	-
Other customers	2.012.959.271	2.191.920.390
Total	6.574.252.885	5.840.952.759

15. Taxes and other obligations to the State Budget

Changes in taxes and other obligations to the State Budget are presented in the attached Appendix 02.

Value added tax (VAT)

The Company has to pay VAT in accordance with the deduction method. The tax rates applied are as follows:

- Medicines, pharmaceutical products of all kinds	5%
- Cosmetics and dietary supplements of all kinds	10%

From 01 January 2025 to 30 June 2025, the Company has been entitled to the VAT rate of 8% on goods and services currently subject to 10% VAT in accordance with Clauses 1 and 2, Article 1, Decree No. 180/2024/NĐ-CP dated 31 December 2024 of the Government.

Corporate income tax

The Company has to pay corporate income tax on taxable income at the rate of 20%.

In 2020, the Company put Binh Hoa Pharmaceutical Factory into operation, which is located in areas with special socio-economic difficulties. Pursuant to the current Law on Corporate Income Tax, the project is entitled to tax incentives at the tax rate of 17% in 10 years for income from business activities in this area; and is exempted from tax in 2 years and reduced by 50% of the tax payable in the following 4 years. The year 2025 was the fourth year that the project was reduced 50% of corporate income tax payable.

Estimated corporate income tax payable during the period is as follows:

	<u>Accumulated from the beginning of the year</u>	<u>Current year</u>	<u>Previous year</u>
Total accounting profit before tax	30.357.347.694		27.201.197.283
Increases/(decreases) of accounting profit to determine profit subject to corporate income tax:			
- Increases	504.694.855		191.083.334
- Decreases	(13.775.089)		-

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

	Accumulated from the beginning of the year	
	Current year	Previous year
Income subject to tax	30.848.267.460	27.392.280.617
Income exempted from tax	(2.374.500)	(2.374.500)
Taxable income	30.845.892.960	27.389.906.117
Corporate income tax rate	20%	20%
Corporate income tax payable at common tax rate	6.169.178.592	5.477.981.223
Differences due to the application of rate other than common tax rate	(68.426.771)	(43.928.912)
Corporate income tax reduced	(193.875.852)	(124.465.251)
Corporate income tax to be paid	5.906.875.969	5.309.587.060

The determination of corporate income tax liability of the Company is based on currently applicable regulations on tax. Nonetheless, these tax regulations may change from time to time and tax regulations applicable to variety of transactions can be interpreted differently. Hence, the tax amounts presented in the Interim Financial Statements can be changed upon the inspection of tax authorities.

Property tax

Property tax is paid according to the notices of the tax department.

Other taxes, fees, legal fees and other duties

The Company has made declaration and payment in line with the prevailing regulations.

16. Short-term accrued expenses

	Ending balance	Beginning balance
Loan interest expenses	521.116.956	555.067.192
Commissions and sales promotions	-	458.536.634
Total	521.116.956	1.013.603.826

17. Short-term unearned revenues

This item reflects proceeds from sales of financial leased assets.

18. Other short-term payables

	Ending balance	Beginning balance
Trade Union's expenditure	321.909.684	317.700.787
Dividends and profit payable	785.182.600	556.935.100
Other short-term payables	317.830.102	216.759.823
Total	1.424.922.386	1.091.395.710

The Company has no other overdue payables.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)**19. Borrowings and financial leases****19a. Short-term borrowings and financial leases**

	<u>Ending balance</u>	<u>Beginning balance</u>
Short-term loans from banks	498.048.627.000	402.406.337.348
- Loan from VietinBank – An Giang Branch ⁽ⁱ⁾	217.570.497.380	200.715.054.767
- Loan from PG Bank – An Giang Branch (formerly known as Petrolimex Petroleum Commercial Joint Stock Bank - An Giang Branch) ⁽ⁱⁱ⁾	14.913.431.627	12.825.860.108
- Loan from Vietcombank – An Giang Branch ⁽ⁱⁱⁱ⁾	99.141.130.105	99.734.098.071
- Loan from Techcombank – An Giang Branch ^(iv)	137.008.828.022	89.131.324.402
- Loan from Shinhan Bank Vietnam Limited - North Saigon Branch ^(v)	29.414.739.866	-
Short-term loans from individuals ^(vi)	400.000.000	400.000.000
Current portions of long-term loans (see Note No. V.19b)	14.400.000.000	-
Current portions of financial leases (see Note No. V.19b)	16.036.381.174	19.951.065.499
Total	528.885.008.174	422.757.402.847

The Company is solvent over short-term loans and financial leases.

- (i) The loan from VietinBank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The term of credit line is 12 months. This loan is secured by mortgaging savings book, debt claims, inventories, buildings and structures, machinery and equipment, vehicles, office equipment and land use right of the Company (see Notes No. V.2b, V.3, V.7, V.9 and V.11).
- (ii) The loan from PG Bank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The term of credit line is 12 months. This loan is secured by mortgaging land use right of the Company (see Note No. V.11).
- (iii) The loan from Vietcombank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The loan term is within 12 months as in each loan acknowledgement. This loan is secured by mortgaging inventories, machinery and equipment and land use right of the Company (see Notes No. V.7, V.9 and V.11).
- (iv) The loan from Techcombank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The loan term is within 12 months as in each loan acknowledgement. This loan is secured by mortgaging inventories of the Company and assets of the third party (see Notes No. V.7 and VII.1a).
- (v) The loan from Shinhan Bank Vietnam Limited - North Saigon Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The loan term is within 09 months as in each loan acknowledgement. This loan is secured by mortgaging assets of the third party (see Note No. VII.1a).
- (vi) The unsecured loan from external individuals and the Company's employees is to supplement the working capital for business operation at the interest rate of 7,5%/year.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

Details of increases/(decreases) of short-term borrowings and financial leases during the period are as follows:

	<u>Beginning balance</u>	<u>Increase during the period</u>	<u>Transfer from long-term borrowings and financial leases</u>	<u>Amount repaid during the period</u>	<u>Ending balance</u>
Short-term loans from banks	402.406.337.348	357.055.483.312	-	(261.413.193.660)	498.048.627.000
Short-term loans from individuals	400.000.000	20.300.000.000	-	(20.300.000.000)	400.000.000
Current portions of long-term loans	-	-	18.000.000.000	(3.600.000.000)	14.400.000.000
Current portions of financial lease	19.951.065.499	-	6.550.065.082	(10.464.749.407)	16.036.381.174
Total	422.757.402.847	377.355.483.312	24.550.065.082	(295.777.943.067)	528.885.008.174

19b. Long-term borrowings and financial leases

	<u>Ending balance</u>	<u>Beginning balance</u>
Long-term loans from banks	96.477.000.000	106.558.000.000
Loan from VietinBank – An Giang Branch ⁽ⁱ⁾	96.477.000.000	106.558.000.000
Financial leases	8.164.883.678	12.011.419.412
36-month financial lease from Chailease International Leasing Company Limited for business operation	4.221.971.311	8.178.994.176
36-month financial lease from Vietnam International Leasing Company Limited for business operation	3.942.912.367	3.832.425.236
Total	104.641.883.678	118.569.419.412

The Company is solvent over long-term loans and financial leases.

- (i) The loan from VietinBank – An Giang Branch is to pay investment costs of the Beta-lactam antibiotic plant project at interest rate applied to each loan acknowledgement. The loan term is 9 years, starting from the first disbursement date. The loan is repaid on quarterly basis and the principal grace period is 16 months. This loan is secured by mortgaging buildings and structures (see Note No. V.9).

Repayment schedule of long-term financial leases is as follows:

	<u>Total debts</u>	<u>1 year or less</u>	<u>More than 1 year to 5 years</u>	<u>More than 5 years</u>
Ending balance				
Long-term loans from banks	110.877.000.000	14.400.000.000	57.600.000.000	38.877.000.000
Financial lease	24.201.264.852	16.036.381.174	8.164.883.678	-
Total	135.078.264.852	30.436.381.174	65.764.883.678	38.877.000.000

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

	Total debts	1 year or less	More than 1 year to 5 years	More than 5 years
Beginning balance				
Financial lease	31.962.484.911	19.951.065.499	12.011.419.412	-
Total	31.962.484.911	19.951.065.499	12.011.419.412	-

Total financial lease payable is as follows:

	1 year or less	More than 1 year to 5 years	Total
Ending balance			
Principal	16.036.381.174	8.164.883.678	24.201.264.852
Interest	1.325.409.767	455.056.953	1.780.466.720
Financial lease payable	17.361.790.941	8.619.940.631	25.981.731.572

Beginning balance			
Principal	19.951.065.499	12.011.419.412	31.962.484.911
Interest	1.971.743.794	724.872.305	2.696.616.099
Financial lease payable	21.922.809.293	12.736.291.717	34.659.101.010

Details of increases/(decreases) of long-term borrowings and financial leases are as follows:

	Beginning balance	Increase during the period	Amount repaid during the period	Transfer to short-term loans and financial leases	Ending balance
Long-term loans from banks	106.558.000.000	7.919.000.000	-	(18.000.000.000)	96.477.000.000
Financial lease	12.011.419.412	2.845.931.867	(142.402.519)	(6.550.065.082)	8.164.883.678
Total	118.569.419.412	10.764.931.867	(142.402.519)	(24.550.065.082)	104.641.883.678

The Company has no overdue loans and financial leases.

20. Bonus and welfare funds

	Beginning balance	Increase due to appropriation from profit	Disbursement during the period	Ending balance
Bonus funds	16.237.162.722	3.667.008.458	(6.244.247.585)	13.659.923.595
Welfare fund	822.867.089	-	(35.000.000)	787.867.089
Bonus fund to the Board of Management and the Supervisory Board	2.568.346	728.871.010	(731.439.356)	-
Total	17.062.598.157	4.395.879.468	(7.010.686.941)	14.447.790.684

21. Owner's equity**21a. Statement of changes in owner's equity**

Information on the changes in owner's equity is presented in the attached Appendix 03.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

21b. Details of owner's capital

	<u>Ending balance</u>	<u>Beginning balance</u>
Imexpharm Corporation	80.346.370.000	73.042.160.000
Mr. Pham Uyen Nguyen	38.154.500.000	34.685.910.000
Mr. Nguyen Van Kha	33.870.460.000	30.692.230.000
Other shareholders	113.781.350.000	93.019.110.000
Total	266.152.680.000	231.439.410.000

During the period, the Company issued shares to distribute its dividends to current shareholders at the rate of 10:01 (a current shareholder holding 10 shares was eligible for receiving 01 additional shares) in line with the Resolution No. 01/NQ-AGP.DHĐCĐ dated 08 March 2025 of Annual General Meeting of Shareholders. Accordingly, the Company recorded an increase in capital and a decrease in retained earnings for an amount of VND 23.141.300.000. The Company has offered 1.157.197 common shares under the Employee Stock Ownership Plan (ESOP) to supplement its business capital, in accordance with Resolution No. 01/NQ-AGP.DHĐCĐ dated 8 March 2025, of the 2025 Annual General Meeting of Shareholders, with a total amount of VND 11.571.970.000. On 23 May 2025, the Company was granted the 19th amended Business Registration Certificate by An Giang Province Department of Planning and Investment regarding the increase in charter capital up to VND 266.152.680.000.

21c. Shares

	<u>Ending balance</u>	<u>Beginning balance</u>
Number of shares registered to be issued	26.615.268	23.143.941
Number of shares sold to the public	26.615.268	23.143.941
- Common shares	26.615.268	23.143.941
- Preferred shares	-	-
Number of shares repurchased	-	-
- Common shares	-	-
- Preferred shares	-	-
Number of outstanding shares	26.615.268	23.143.941
- Common shares	26.615.268	23.143.941
- Preferred shares	-	-

Face value per outstanding share: VND 10.000.

21d. Profit distribution

During the period, the Company distributed profit of 2024 in line with the Resolution No. 01/NQ-AGP.DHĐCĐ dated 08 March 2025 of 2025 Annual General Meeting of Shareholders as follows:

	<u>VND</u>
• Dividend distribution in form of shares (47,34% Profit after tax 2024) :	23.143.941.000
• Dividend distribution in form of cash (23,67% Profit after tax 2024) :	11.571.970.500
• Appropriation for bonus and welfare funds (7,5% Profit after tax 2024) :	3.667.008.458
• Appropriation for bonus fund to the Board of Management and the Supervisory Board (1,49% Profit after tax 2024) :	728.871.010
• Appropriation for investment and development fund (20% Profit after tax 2024) :	9.777.947.742

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

During the period, the Company paid dividends to the shareholders as follows:

	Accumulated from the beginning of the year	
	Current year	Previous year
Dividends in the previous year	11.343.723.000	401.175.020
Total	11.343.723.000	401.175.020

22. Off-Interim Balance Sheet items**Foreign currencies**

As of the balance sheet date, cash and cash equivalents include USD 67.891,95 (beginning balance: USD 9.409,98).

VI. ADDITIONAL INFORMATION ON THE ITEMS OF THE INTERIM INCOME STATEMENT**1. Revenue from sales of goods and provisions of services****1a. Gross revenue**

	Accumulated from the beginning of the year	
	Current year	Previous year
Revenue from sales of merchandise	2.046.847.470	1.954.484.051
Revenue from sales of finished goods	407.736.216.867	373.014.540.028
Total	409.783.064.337	374.969.024.079

1b. Revenue from sales of goods and provisions of services to related parties

Apart from sales of goods and service provisions to the joint venture presented in Note No. V.2c. the Company only has sales of goods and service provisions to Imexpharm Corporation (the major shareholder of the Company) for an amount of VND 12.380.518.618 (previous period: VND 10.778.967.202).

2. Revenue deductions

	Accumulated from the beginning of the year	
	Current year	Previous year
Trade discounts	1.115.668.282	674.579.970
Sales returns	726.372.960	3.119.861.317
Sales allowances	15.582.789	165.804.389
Total	1.857.624.031	3.960.245.676

3. Costs of sales

	Accumulated from the beginning of the year	
	Current year	Previous year
Costs of merchandise	1.529.706.848	1.389.797.017
Costs of finished goods sold	290.222.412.143	264.593.141.935
Total	291.752.118.991	265.982.938.952

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)**4. Financial income**

	Accumulated from the beginning of the year	
	Current year	Previous year
Demand deposit interest	15.282.887	22.277.589
Term deposit interest	103.561.644	219.284.932
Dividends and profit received	2.374.500	2.374.500
Exchange gain arising	120.399.214	14.817.590
Other income	32.735.363	-
Total	274.353.608	258.754.611

5. Financial expenses

	Accumulated from the beginning of the year	
	Current year	Previous year
Loan interest expenses	18.880.133.246	14.217.692.368
Exchange loss arising	334.192.210	306.018.708
Cash discount given to customers	1.311.260.939	1.275.096.509
Exchange loss due to the revaluation of monetary items in foreign currencies	330.989.924	37.966.282
Total	20.856.576.319	15.836.773.867

6. Selling expenses

	Accumulated from the beginning of the year	
	Current year	Previous year
Expenses for employees	7.061.096.114	6.890.084.108
Tools, supplies	151.320.105	143.991.233
Depreciation/(amortization) of fixed assets	1.319.937.644	1.321.724.233
Expenses for external services	34.659.708.260	31.022.833.300
<i>Commission, discount, promotion, advertisement</i>	<i>31.471.886.851</i>	<i>27.359.699.453</i>
<i>Other expenses for external services</i>	<i>3.187.821.409</i>	<i>3.663.133.847</i>
Other expenses	3.722.071.135	3.241.270.952
Total	46.914.133.258	42.619.903.826

7. General and administration expenses

	Accumulated from the beginning of the year	
	Current year	Previous year
Expenses for employees	11.928.455.645	10.749.642.139
Office stationery	1.855.910.446	1.444.305.500
Depreciation/(amortization) of fixed assets	474.650.822	818.189.816
Taxes, fees and legal fees	57.200.126	419.130.719
Allowance for doubtful debts	277.861.521	87.494.970
Expenses for external services	3.612.404.457	2.920.966.273
Other expenses	3.271.706.268	2.992.350.403
Total	21.478.189.285	19.432.079.820

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)**8. Other income**

	Accumulated from the beginning of the year	
	Current year	Previous year
Proceeds from liquidation, disposal of fixed assets	2.769.892.748	-
Collection of fees for testing, storage	203.377.764	100.492.722
Other income	185.416.121	1.426.720
Total	3.158.686.633	101.919.442

9. Other expenses

	Accumulated from the beginning of the year	
	Current year	Previous year
Loss on liquidation and disposal of fixed assets	-	241.370.708
Other expenses	115.000	55.188.000
Total	115.000	296.558.708

10. Earnings per share**10a. Basic/diluted earnings per share**

	Accumulated from the beginning of the year	
	Current year	Previous year
Accounting profit after corporate income tax	24.450.471.725	21.891.610.223
Appropriation for bonus and welfare funds (*)	(1.833.785.379)	(1.506.142.783)
Appropriation for bonus for the Board of Management and the Supervisory Board (*)	(364.312.029)	(278.023.450)
Profit used to calculate basic/diluted earnings per share	22.252.374.317	20.107.443.990
The weighted average number of ordinary shares outstanding during the period	25.702.368	25.458.071
Basic/diluted earnings per share	866	790

(*) Bonus and welfare funds and bonus for the Board of Management, the Supervisory Board in the current period are temporarily appropriated at the rate as stipulated in the Resolution No. 01/NQ-AGP.DHĐCĐ dated 08 March 2025 of 2025 Annual General Meeting of Shareholders.

The number of ordinary shares used to calculate basic/diluted earnings per share is determined as follows:

	Accumulated from the beginning of the year	
	Current year	Previous year
The weighted average number of ordinary shares outstanding during the period	23.143.941	20.664.453
Effects of ordinary shares issued during the period	2.558.427	4.793.618
Average ordinary shares outstanding during the period	25.702.368	25.458.071

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)**10b. Other information**

On 23 May 2025, the Company increased its charter capital from retained earnings. The basic/diluted earnings per share for the previous period were adjusted due to the effect of this event. As a result of this adjustment, the basic/diluted earnings per share for the previous period decreased from VND 949 to VND 790.

11. Operating costs by factors

	Accumulated from the beginning of the year	
	Current year	Previous year
Materials and supplies	265.199.830.901	220.456.094.554
Labor costs	37.416.439.507	34.751.598.547
Depreciation/(amortization) of fixed assets	18.433.774.920	16.303.533.395
Expenses for external services	44.351.251.841	40.364.259.743
Other expenses	8.365.197.418	6.725.114.512
Total	373.766.494.587	318.600.600.751

VII. OTHER DISCLOSURES**1. Transactions and balances with related parties**

The Company's related parties include the key managers, their related individuals and other related parties.

1a. Transactions and balances with the key managers and their related individuals

The Company's key managers include the Board of Management and the Board of Directors. The key managers' related individuals are their close family members.

Transactions with the key managers and their related individuals

The Company has no sales of goods to the key managers and their related individuals and only has following transactions with the key managers:

	Accumulated from the beginning of the year	
	Current year	Previous year
Collection of capital contribution from dividends payment in form of shares	7.357.380.000	8.360.310.000
Dividends payment in cash	(3.678.699.000)	-

Guarantee commitment

The Company's key managers used their assets to secure the Company's loans from Banks (see Note No. V.19a).

Receivables from and payables to the key managers and their related individuals

The Company has no receivables from and payables to the key managers and their related individuals.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)*Remuneration of the key managers and the Supervisory Board:*

Full name	Position	Accumulated from the beginning of the year	
		Current year	Previous year
Ms. Pham Thi Bich Thuy	Chairwoman cum Deputy General Director	218.940.950	217.953.600
Mr. Nguyen Van Kha	Vice Chairman cum General Director	394.000.000	368.000.000
Mr. Huynh Hoang Ha	Member cum Deputy General Director	229.479.880	195.675.840
Ms. Tran Thi Dao	Board Member	105.000.000	90.000.000
Mr. Nguyen Quoc Dinh	Board Member	105.000.000	90.000.000
Mr. Pham Uyen Nguyen	Board Member	105.000.000	90.000.000
Mr. Lam Tri Hien	Deputy General Director	64.642.240	64.639.320
Mr. Vu Minh Tuan	Deputy General Director	82.639.411	82.021.266
Ms. Tran Thi Thanh Hang	Head of the Supervisory Board	104.000.000	89.000.000
Ms. Pham Hai Yen	Member of the Supervisory Board	15.303.360	50.224.468
Ms. Nguyen Hong Ngoc	Member of the Supervisory Board	18.000.000	16.000.000
Total		1.442.005.841	1.353.514.494

1b. Transactions and balances with other related parties

Other related parties of the Company include:

Other related parties	Relationship
Imexpharm Corporation	The major shareholder holding 30,19% of charter capital
USA-AGP Pharma, LLC	Joint venture

Transactions with other related parties

Apart from transactions with the joint venture presented in Note No. V.2c as well as sales of goods and service provisions to other related parties presented in Note No. VI.1b, the Company only has following transactions with Imexpharm Corporation:

	Accumulated from the beginning of the year	
	Current year	Previous year
Purchase of goods	10.412.468.510	2.288.209.601
Storage fee	163.636.364	-
Dividend payment in form of shares	7.304.210.000	7.825.940.000
Dividends payment in cash	(3.652.108.000)	-

The prices of merchandise supplied to other related parties are market prices. The purchases of merchandises from other related parties are done at the mutually agreed prices.

Receivables from and payables to other related parties

The receivables from and payables to other related parties are presented in Notes No. V.3 and V.13.

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Notes to the Interim Financial Statements (cont.)

The receivables from other related parties are unsecured and will be paid in cash. There are no allowances for doubtful debts made for the receivables from other related parties.

2. Segment information

Segment information is presented based on business segments and geographical segments. Segment reporting is mainly done on the basis of business segments since the Company's business operations are organized and managed on the basis of the nature of its products.

2a. Information on business segment

Principal business activity of the Company is to trade finished medicines of all kinds. Additionally, other business activity of the Company is mainly to sell goods and materials. Sales from other business activity only account for a very small proportion of gross sales (0,49% of gross sales for the first 6 months of 2025). Sales and costs of business activities are presented in Notes No. VI.1a and VI.3.

2b. Information on geographical segment

The Company's operations include exports and local sales.

Details of net external sales in respect of geographical segment based on the location of customers are as follows:

	Accumulated from the beginning of the year	
	Current year	Previous year
Local areas	403.919.490.514	370.063.347.177
Overseas countries	4.005.949.792	945.431.226
Total	407.925.440.306	371.008.778.403

3. Subsequent events

There are no material subsequent events which are required adjustments or disclosures in the Interim Financial Statements.

Do Thi Kim Len
Preparer

Tran Nguyen Minh Hien
Chief Accountant



Nguyen Van Kha
General Director

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Appendix 01: Increases, decreases in tangible fixed assets

	Unit: VND				
	Buildings and structures	Machinery and equipment	Vehicles	Office equipment	Total
Historical costs					
Beginning balance	343.513.660.916	106.373.311.435	14.744.430.215	3.203.966.886	467.835.369.452
Acquisition during the period	1.752.066.889	4.254.141.316	-	-	6.006.208.205
Completed constructions	-	462.605.000	-	-	462.605.000
Liquidation and disposal	-	(2.979.315.667)	-	-	(2.979.315.667)
Ending balance	345.265.727.805	108.110.742.084	14.744.430.215	3.203.966.886	471.324.866.990
<i>In which:</i>					
Assets fully depreciated but still in use	14.903.487.493	29.471.593.364	7.100.744.485	809.914.517	52.285.739.859
Assets waiting for liquidation	-	-	-	-	-
Depreciation					
Beginning balance	51.926.160.712	71.299.172.974	10.530.932.329	1.418.064.684	135.174.330.699
Depreciation during the period	8.081.107.079	4.294.731.748	624.086.041	168.055.382	13.167.980.250
Liquidation and disposal	-	(131.394.000)	-	-	(131.394.000)
Ending balance	60.007.267.791	75.462.510.722	11.155.018.370	1.586.120.066	148.210.916.949
Carrying values					
Beginning balance	291.587.500.204	35.074.138.461	4.213.497.886	1.785.902.202	332.661.038.753
Ending balance	285.258.460.014	32.648.231.362	3.589.411.845	1.617.846.820	323.113.950.041
<i>In which:</i>					
Assets temporarily not in use	-	-	-	-	-
Assets waiting for liquidation	-	-	-	-	-


Do Thi Kim Len
Preparer

Tran Nguyen Minh Hien
Chief Accountant

An Giang, 06 August 2025

**CÔNG TY
CP
DƯỢC PHẨM
AGIMEXPHARM**

Nguyen Van Kha
General Director

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Appendix 02: Changes in taxes and other obligations to the State Budget


Unit: VND

	Beginning balance		Increase during the period		Ending balance	
	Payables	Receivables	Amount payable	Amount paid	Payables	Receivables
VAT on local sales	-	-	61.818.182	(61.818.182)	-	-
Export-import duties	-	-	14.201.690	(18.857.781)	-	4.656.091
Corporate income tax	11.452.443.463	-	5.906.875.969	(11.722.011.234)	5.637.308.198	-
Personal income tax	65.744.032	-	3.161.351.029	(3.020.258.234)	206.836.827	-
Property tax	-	-	1.200.128	(1.200.128)	-	-
Other taxes	-	-	33.333.332	(33.333.332)	-	-
Fees, legal fees and other duties	-	-	16.000.000	(16.000.000)	-	-
Total	11.518.187.495	-	9.194.780.330	(14.873.478.891)	5.844.145.025	4.656.091


Do Thi Kim Len
Preparer

Tran Nguyen Minh Hien
Chief Accountant

An Giang, 06 August 2025


 Nguyen Van Kha
General Director

AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

INTERIM FINANCIAL STATEMENTS

For the first 6 months of the fiscal year ending 31 December 2025

Appendix 03: Statement of changes in owner's equity

Unit: VND

	Owner's capital	Share premiums	Investment and development fund	Retained earnings	Total
Beginning balance of the previous year	206.644.530.000	25.726.714.700	78.700.305.421	43.612.786.683	354.684.336.804
Payment of dividends in form of shares in the previous period	24.794.880.000	-	-	(24.794.880.000)	-
Profit in the previous period	-	-	-	21.891.610.223	21.891.610.223
Appropriation for funds in the previous period	-	-	15.264.475.339	(18.815.446.683)	(3.550.971.344)
Disbursement in the previous period	-	-	(25.961.301)	-	(25.961.301)
Transfer of fractional shares from Payment of dividends in form of shares to Bonus fund	-	-	-	(2.460.000)	(2.460.000)
Ending balance of the previous period	231.439.410.000	25.726.714.700	93.938.819.459	21.891.610.223	372.996.554.382
Beginning balance of the current year	231.439.410.000	25.726.714.700	93.803.543.069	48.889.738.710	399.859.406.479
Payment of dividends in form of shares in the current period	23.141.300.000	-	-	(23.141.300.000)	-
Issuance of shares collected in cash in the current period	11.571.970.000	9.257.576.000	-	-	20.829.546.000
Profit in the current period	-	-	-	24.450.471.725	24.450.471.725
Appropriation for funds in the current period	-	-	9.777.947.742	(14.173.827.210)	(4.395.879.468)
Dividends and profit in the current period	-	-	-	(11.571.970.500)	(11.571.970.500)
Disbursement in the current period	-	-	(33.206.628)	-	(33.206.628)
Transfer of fractional shares from Payment of dividends in form of shares to Investment and development fund	-	-	2.641.000	(2.641.000)	-
Ending balance of the current period	266.152.680.000	34.984.290.700	103.550.925.183	24.450.471.725	429.138.367.608



Do Thi Kim Len
Preparer



Tran Nguyen Minh Hien
Chief Accountant

An Giang, 06 August 2025

CÔNG TY CP
DƯỢC PHẨM
AGIMEXPHARM

NGUYỄN VĂN KHÁ
General Director